Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Shaanxi Province, China.
Sci Rep. 2024 Jan 30;14(1):2461. doi: 10.1038/s41598-024-51292-4.
Interferon therapy is the most effective treatment for achieving clinical cure in chronic hepatitis B (CHB) patients. However, the treatment outcomes of interferon therapy are uncertain, multiple side effects can occur during treatment, and the treatment is expensive. Although these characteristics may affect patients' quality of life, research examining this topic is limited. We used a cross-sectional design to examine 100 CHB patients receiving interferon, 100 receiving nucleoside/nucleotide analogues, and 87 receiving non-antiviral treatment. Characteristic information, the Hepatitis B Quality of Life Instrument, Connor Davidson Resilience Scale, and Work Productivity and Activity Impairment Questionnaire were used to collect information. We found that quality of life in the interferon treatment group was higher than that in the non-antiviral treatment and nucleoside/nucleotide analogue treatment groups (p < 0.05). The factors influencing quality of life were resilience, presenteeism, hair loss, and antiviral treatment (p < 0.05). Although interferon therapy has some potential side effects, the results suggested that it did not negatively affect quality of life. Overall, interferon therapy did not have a major impact on CHB patients' daily lives and work.
干扰素治疗是慢性乙型肝炎（CHB）患者实现临床治愈最有效的治疗方法。然而，干扰素治疗的治疗效果并不确定，治疗过程中可能会出现多种副作用，且治疗费用昂贵。尽管这些特点可能会影响患者的生活质量，但针对这一主题的研究有限。我们采用横断面设计，对 100 例接受干扰素治疗、100 例接受核苷（酸）类似物治疗和 87 例接受非抗病毒治疗的 CHB 患者进行了研究。采用特征信息、乙型肝炎生活质量量表、Connor-Davidson 韧性量表和工作效率和活动障碍问卷收集信息。我们发现干扰素治疗组的生活质量高于非抗病毒治疗组和核苷（酸）类似物治疗组（p<0.05）。影响生活质量的因素有韧性、现患率、脱发和抗病毒治疗（p<0.05）。尽管干扰素治疗有一些潜在的副作用，但结果表明它并没有对生活质量产生负面影响。总的来说，干扰素治疗对 CHB 患者的日常生活和工作没有产生重大影响。
